<DOC>
	<DOCNO>NCT02710734</DOCNO>
	<brief_summary>The purpose study evaluate bladder preserve approach patient muscle invasive bladder cancer use neoadjuvant accelerated Methotrexate , Vinblastine , Doxorubicin , Cisplatin ( AMVAC ) follow chemoradiation intensity modulate radiation therapy ( IMRT ) 5-Fluorouracil ( 5-FU ) Mitomycin C. Patients maximal transurethral resection , follow three cycle AMVAC . Once AMVAC complete , patient second maximal transurethral resection , chemoradiation IMRT 5-FU Mitomycin C , follow third maximal transurethral resection . Tolerability efficacy evaluate physical exam , adverse event assessment , quality life questionnaire , lab , CT/bone scan . Patients follow 5 year status post completion therapy .</brief_summary>
	<brief_title>Trimodality Bladder Preservation Therapy : Maximal Transurethral Resection Followed Accelerated Methotrexate , Vinblastine , Doxorubicin , Cisplatin ( AMVAC ) Concurrent Chemoradiation With Intensity Modulated Radiation Therapy Muscle Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Male female patient ≥18 year . Primary urothelial predominantly urothelial carcinoma bladder . Histologic evidence muscularis propria invasion . AJCC27 clinical stage T2T4a . No radiographic evidence lymph node positivity ( N0 ) metastatic disease ( M0 ) . Clinical lymphadenopathy stag CT great 1.5 cm short axis must biopsy proven negative . ECOG performance status 0 , 1 , 2 . Left ventricular ejection fraction ≥ 50 % MUGA ECHO within 6 month study entry . Normal organ bone marrow function define : Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin ≤ institutional upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X institutional ULN Creatinine Creatinine Clearance ≥ 50 mL/min ( calculate use CockroftGault formula measure 24 hour urine collection ) Any component small cell histology . Prior pelvic radiation therapy patient undergone prior radiation great equal 25 % bone marrow within past year exclude due risk life threaten myelosuppression Prior systemic chemotherapy ; patient receive previous systemic chemotherapy radiation therapy urothelial carcinoma cytotoxic chemotherapy another malignancy within 1 year study entry ineligible . Prior concurrent malignancy site except nonmelanoma skin cancer , unless disease free interval ≥ 5 year . Patients receive experimental agent within 4 week study entry . History allergic reaction attribute compound similar chemical biologic composition Methotrexate , Vinblastine , Adriamycin Cisplatin agent use study Uncontrolled intercurrent illness include , limited , ongoing active infection ( define current oral intravenous antibiotic therapy ) , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study due potential teratogenic abortifacient effect cytotoxic chemotherapy . Known HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction cytotoxic chemotherapy . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Patients hydronephrosis address intervention placement stent . Pregnancy &amp; Women Childbearing Potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Urothelial</keyword>
</DOC>